Proxygen is focused on discovering glue degraders, which are small molecules that facilitate the degradation of target proteins in cells, potentially offering new treatment options for diseases. self-described as a team of explorers deeply rooted in science.

Proxygen

Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation, primarily investing in pioneering science that offers potential benefits for patients.

Boehringer Ingelheim Venture Fund

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly

Eli Lilly and Company

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Metric
Company Name	Proxygen	Boehringer Ingelheim Venture Fund	Eli Lilly and Company	Merck & Co., Inc.
Symbol			LLY	MRK
MSH ID	COM:PROXYGEN	COM:BOEHRINGER-INGELHEIM-VENTURE	COM:LILLY	COM:MERCK
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Financial Services & Finance	Healthcare	Healthcare
Industry	Biotechnology	Venture Capital	Drug Manufacturers - General	Drug Manufacturers - General
Country	US	DE	US	US
Stage				Post-IPO Equity
Employee Count			43K	70K
Website	proxygen.com	boehringer-ingelheim-venture.com	lilly.com	merck.com
LinkedIn				merck
Founders

Metric
Market Cap	893.17B	322.43B
Enterprise Value
Monthly Web Traffic		1.08M
Web Traffic Growth		0.20
Valuation
Raised Capital		586K

Metric
Revenue	34.12B	59.87B
Revenue (LTM)
Revenue (NTM)
Gross Profit	27.55B	43.89B
EBITDA	12.46B	6.85B
Operating Income	10.33B	2.98B
Net Income	5.24B	365M
EPS	5.82	0.14
Diluted EPS	5.80	0.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81	0.76
Operating Profit Margin	0.27	0.28
EBITDA Margin	0.37	0.11
Net Profit Margin	0.23	0.22
Return on Equity	0.61	0.35
Return on Assets	0.10	0.14
Return on Capital Employed	0.23	0.24

PROX

COM:PROXYGEN

Proxygen

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	127.25	69.75
P/B Ratio	56.57	7.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	27.04	5.48
EV Multiple	115.09	50.06

Metric
Days Sales Outstanding	117.94	63.96
Days Payables Outstanding	129.90	79.58
Days Inventory Outstanding	327.50	160.67
Operating Cycle	452.72	234.12
Cash Conversion Cycle	323.73	147.39
Asset Turnover	0.56	0.62

Metric
Operating Cash Flow	4.24B	13.01B
Free Cash Flow	-3.15B	9.14B
Cash Flow to Debt	0.17	0.44
Operating Cash Flow/Sales	0.14	0.27
Free Cash Flow Yield	-0.00	0.04

Metric
Cash & Equivalents	2.82B	6.91B
Accounts Receivable	-2.45B	-1.15B
Inventory	5.77B	6.36B
Goodwill	4.94B	21.20B
Debt to Capitalization	0.70	0.48
Debt to Assets	0.35	0.33
Current Ratio	1.05	1.38
Quick Ratio	1.03	1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.01
R&D to Revenue	0.27	0.42
SG&A to Revenue	0.22